Luc J. J. Derijks

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

Marieke J. H. Coenen, Dirk J. de Jong, Corine J. van Marrewijk et al. · Gastroenterology · 2015 · 197 citations · Full text

Medicine, Hematology, Pharmacology +14

Inosine Triphosphate Pyrophosphatase and Thiopurine S-Methyltransferase Genotypes Relationship to Azathioprine-Induced Myelosuppression

Zuzana Zelinková, Luc J. J. Derijks, Pieter Stokkers et al. · Clinical Gastroenterology and Hepatology · 2006 · 152 citations · Full text

Medicine, Genetics, Pharmacology +16

Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease

Luc J. J. Derijks, Lennard P. L. Gilissen, L.G.J.B. Engels et al. · Therapeutic Drug Monitoring · 2004 · 121 citations

Medicine, Pharmacokinetics, Pharmacology +13

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients

Luc J. J. Derijks, Dirk J. de Jong, Lennard PL Gilissen et al. · European Journal of Gastroenterology & Hepatology · 2003 · 74 citations

Medicine, Pharmacology, Pharmacotherapy +13

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

E.M.H. Schmitz, Paul J. Boekema, Jan-Willem Straathof et al. · Alimentary Pharmacology & Therapeutics · 2017 · 70 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +13